| Publisher’s Note: Join us September 11-14 in Philadelphia for Digital Pharma East! We’re excited to announce our opening keynote, none other than Dustin Garis, world-renowned brand innovator, customer experience pioneer and Chief Troublemaker. Register today for the ultimate marketing event in the life sciences industry. |
Today's Big NewsAug 1, 2023 |
|
October 5-6, 2023 San Diego, CA Join us at the Fierce Medical Affairs Strategic Summit West and hear industry-leading speakers from Amgen, Abbott, Bayer, Gilead, Janssen, Otsuka, Daiichi Sankyo, and many more. Register now with early bird rates and save $200. .png) |
|
| By Nick Paul Taylor Pfizer is ringing the changes as it exits the second quarter, tossing out a midstage pneumococcal vaccine candidate and a handful of phase 1 assets including a respiratory syncytial virus prospect it picked up in last year’s ReViral takeover. |
|
|
|
| Philadelphia, PA |  |
|
|
By Max Bayer The FDA's Peter Marks, M.D., Ph.D., thinks gene editing—specifically base editing—could be a "game changer," but progress has been slow, likely due to discouragement with the regulatory process. |
By James Waldron EQRx's mission to revolutionize drug pricing has come to an end with another type of revolution: an acquisition, to be exact. The Alexis Borisy biotech will be acquired by another of the serial biotech founder's startups, Revolution Medicines. |
By Gabrielle Masson While facing a mutiny led by former CFO Christopher Riley, Nymox Pharmaceutical is claiming that Riley attempted to swindle the company of 100,000 stock shares and tried to promote one of the “very worst offers” the company has seen. |
By Max Bayer Esperion is calling it quits on a two-and-a-half-year partnership with Serometrix on an oral PCSK9 candidate. Serometrix was supplying Esperion with scaffolding compounds that could be used in the small molecule. |
By James Waldron Indivior has paid 15.95 million pounds sterling ($20.4 million) to C4X Discovery for the full rights to the British biotech’s orexin-1 receptor antagonist being developed for substance use disorder. |
By Nick Paul Taylor ProQR Therapeutics has found a buyer for its ophthalmology assets. One year after putting the programs up for sale, the Dutch biotech has offloaded sepofarsen and ultevursen to Laboratoires Théa for 12.5 million euros ($13.7 million) upfront. |
By Helen Floersh Researchers have created a battery-powered device that stimulates gene expression and prompts cells to produce insulin in diabetic mice, cracking open a door to a future where wearable electronics could program cell and gene therapies. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Conor Hale Listed for sale on the clinical testing giant's website, the AD-Detect beta amyloid test retails for $399. |
By Joseph Keenan Lupin Pharmaceuticals, the U.S. unit of India’s Lupin Limited, issued a voluntary recall of two lots of birth control pills due to the potential that they may not be effective in preventing pregnancy. |
By Angus Liu GSK has won the first FDA approval for an immunotherapy to treat certain patients with newly diagnosed endometrial cancer. But the industry-first go-ahead is tempered with a label limitation. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we revisit an episode on Narcan the nasal spray. It is the first naloxone product to be approved for use without a prescription. |
|
|---|
|
|
Whitepaper Leading facilities practices and technologies can help improve the productivity of your research and manufacturing operations—and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Research Learn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Webinar Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
Whitepaper Learn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
| |
|
